Tandem Diabetes Care (TNDM) Competitors

Tandem Diabetes Care logo
$18.48 -1.59 (-7.92%)
Closing price 04:00 PM Eastern
Extended Trading
$18.70 +0.22 (+1.21%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TNDM vs. LIVN, IRTC, ITGR, PLSE, and ATRC

Should you buy Tandem Diabetes Care stock or one of its competitors? Tandem Diabetes Care's main competitors and comparable companies include LivaNova (LIVN), iRhythm Technologies (IRTC), Integer (ITGR), Pulse Biosciences (PLSE), and AtriCure (ATRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Tandem Diabetes Care compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

97.6% of LivaNova shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LivaNova has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

In the previous week, Tandem Diabetes Care had 11 more articles in the media than LivaNova. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 10 mentions for LivaNova. Tandem Diabetes Care's average media sentiment score of 1.05 beat LivaNova's score of 0.55 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LivaNova
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tandem Diabetes Care
11 Very Positive mention(s)
7 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LivaNova has a net margin of 13.01% compared to Tandem Diabetes Care's net margin of -4.58%. LivaNova's return on equity of 16.10% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
LivaNova13.01% 16.10% 7.85%
Tandem Diabetes Care -4.58%-35.61%-4.53%

Tandem Diabetes Care has lower revenue, but higher earnings than LivaNova. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.39B3.62-$242.47M$3.0030.44
Tandem Diabetes Care$1.01B1.38-$204.71M-$0.72N/A

LivaNova currently has a consensus target price of $101.22, indicating a potential upside of 10.84%. Tandem Diabetes Care has a consensus target price of $27.18, indicating a potential upside of 35.45%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75
Tandem Diabetes Care
1 Sell rating(s)
12 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.43

Summary

LivaNova beats Tandem Diabetes Care on 9 of the 16 factors compared between the two stocks.

How does Tandem Diabetes Care compare to iRhythm Technologies?

Tandem Diabetes Care (NASDAQ:TNDM) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

In the previous week, Tandem Diabetes Care had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 20 mentions for iRhythm Technologies. Tandem Diabetes Care's average media sentiment score of 1.05 beat iRhythm Technologies' score of 0.20 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tandem Diabetes Care
11 Very Positive mention(s)
7 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
iRhythm Technologies
2 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

iRhythm Technologies has a net margin of -4.52% compared to Tandem Diabetes Care's net margin of -4.58%. iRhythm Technologies' return on equity of 26.88% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-4.58% -35.61% -4.53%
iRhythm Technologies -4.52%26.88%4.32%

Tandem Diabetes Care has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

Tandem Diabetes Care currently has a consensus price target of $27.18, suggesting a potential upside of 35.45%. iRhythm Technologies has a consensus price target of $164.07, suggesting a potential upside of 78.51%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than Tandem Diabetes Care.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
12 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.43
iRhythm Technologies
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

iRhythm Technologies has lower revenue, but higher earnings than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.01B1.38-$204.71M-$0.72N/A
iRhythm Technologies$747.14M4.14-$44.55M-$1.17N/A

Summary

iRhythm Technologies beats Tandem Diabetes Care on 8 of the 14 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Integer?

Integer (NYSE:ITGR) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Integer has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

In the previous week, Tandem Diabetes Care had 19 more articles in the media than Integer. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 2 mentions for Integer. Integer's average media sentiment score of 1.88 beat Tandem Diabetes Care's score of 1.05 indicating that Integer is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Integer
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Tandem Diabetes Care
11 Very Positive mention(s)
7 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Integer has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integer$1.85B2.32$102.81M$2.9842.50
Tandem Diabetes Care$1.01B1.38-$204.71M-$0.72N/A

Integer has a net margin of 5.68% compared to Tandem Diabetes Care's net margin of -4.58%. Integer's return on equity of 11.84% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Integer5.68% 11.84% 5.98%
Tandem Diabetes Care -4.58%-35.61%-4.53%

Integer presently has a consensus target price of $113.67, suggesting a potential downside of 10.25%. Tandem Diabetes Care has a consensus target price of $27.18, suggesting a potential upside of 35.45%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than Integer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integer
0 Sell rating(s)
11 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.08
Tandem Diabetes Care
1 Sell rating(s)
12 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.43

99.3% of Integer shares are held by institutional investors. 1.1% of Integer shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Integer beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Tandem Diabetes Care has a net margin of -4.58% compared to Pulse Biosciences' net margin of -5,603.88%. Tandem Diabetes Care's return on equity of -35.61% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Pulse Biosciences-5,603.88% -77.88% -67.89%
Tandem Diabetes Care -4.58%-35.61%-4.53%

77.0% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pulse Biosciences has higher earnings, but lower revenue than Tandem Diabetes Care. Pulse Biosciences is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulse Biosciences$350K10,599.61-$72.78M-$1.21N/A
Tandem Diabetes Care$1.01B1.38-$204.71M-$0.72N/A

Pulse Biosciences presently has a consensus target price of $66.60, suggesting a potential upside of 32.04%. Tandem Diabetes Care has a consensus target price of $27.18, suggesting a potential upside of 35.45%. Given Tandem Diabetes Care's higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Pulse Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Tandem Diabetes Care
1 Sell rating(s)
12 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.43

In the previous week, Tandem Diabetes Care had 14 more articles in the media than Pulse Biosciences. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 7 mentions for Pulse Biosciences. Tandem Diabetes Care's average media sentiment score of 1.05 beat Pulse Biosciences' score of 0.33 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulse Biosciences
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tandem Diabetes Care
11 Very Positive mention(s)
7 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

Summary

Tandem Diabetes Care beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Tandem Diabetes Care compare to AtriCure?

Tandem Diabetes Care (NASDAQ:TNDM) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Tandem Diabetes Care had 14 more articles in the media than AtriCure. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 7 mentions for AtriCure. Tandem Diabetes Care's average media sentiment score of 1.05 beat AtriCure's score of 0.72 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tandem Diabetes Care
11 Very Positive mention(s)
7 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AtriCure
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tandem Diabetes Care presently has a consensus price target of $27.18, suggesting a potential upside of 35.45%. AtriCure has a consensus price target of $62.30, suggesting a potential upside of 9.61%. Given Tandem Diabetes Care's higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than AtriCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
12 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.43
AtriCure
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.58

AtriCure has a net margin of 2.52% compared to Tandem Diabetes Care's net margin of -4.58%. AtriCure's return on equity of 4.01% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-4.58% -35.61% -4.53%
AtriCure 2.52%4.01%3.03%

AtriCure has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.01B1.38-$204.71M-$0.72N/A
AtriCure$534.53M5.41-$11.45M$0.30189.47

99.1% of AtriCure shares are held by institutional investors. 2.1% of Tandem Diabetes Care shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tandem Diabetes Care has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Summary

AtriCure beats Tandem Diabetes Care on 10 of the 16 factors compared between the two stocks.

Get Tandem Diabetes Care News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNDM vs. The Competition

MetricTandem Diabetes CareHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.22B$5.95B$7.85B$12.17B
Dividend YieldN/A1.69%2.46%4.41%
P/E RatioN/A35.6832.9127.37
Price / Sales1.275.448.595.73
Price / CashN/A23.9521.9322.50
Price / Book9.534.374.403.70
Net Income-$204.71M$143.12M$3.52B$392.17M
7 Day Performance1.71%-4.86%-5.34%-4.53%
1 Month Performance13.79%-2.87%-3.61%-5.86%
1 Year Performance-0.70%-0.76%0.01%-7.78%

Tandem Diabetes Care Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNDM
Tandem Diabetes Care
2.9575 of 5 stars
$18.48
-7.9%
$27.18
+47.1%
+7.8%$1.22B$1.01BN/A2,500
LIVN
LivaNova
2.7447 of 5 stars
$92.61
+2.9%
$101.22
+9.3%
+65.0%$5.19B$1.39B25.813,300
IRTC
iRhythm Technologies
3.5168 of 5 stars
$88.73
-1.7%
$166.93
+88.1%
-46.2%$4.42B$747.14M291.302,400
ITGR
Integer
1.0066 of 5 stars
$126.62
+0.0%
$113.67
-10.2%
+82.4%$4.31B$1.85B21.4611,000
PLSE
Pulse Biosciences
3.4342 of 5 stars
$58.17
+9.2%
$66.60
+14.5%
+250.3%$4.04B$350KN/A116

Related Companies and Tools


This page (NASDAQ:TNDM) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners